Tarsus Pharmaceuticals, Inc. TARS Tenant improvement allowance
Tenant improvement allowance at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:LesseeTenantImprovementAllowance.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
the Company became entitled to base rent abatement for the first five full calendar months for an aggregate amount of $0.7 million. The Current Lease also provides a tenant improvement allowance, not to exceed approximately $5.8 million, and to be applied toward construction costs of the premises. The tenant improvement allowance must be used within one year of the Current Lease commencement date, after which any unused portion will be forfeited with no further obligation by the landlord. As of June 30, 2026, the landlord paid $5.3 million of the tenant improvement allowance.
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s tenant improvement allowance?
- Tarsus Pharmaceuticals, Inc. (TARS) reported tenant improvement allowance of $5.8M in Q4 2024.
- What does tenant improvement allowance mean?
- Tenant improvement allowance as reported by Tarsus Pharmaceuticals, Inc. Common Stock.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s tenant improvement allowance.
Connect your AI assistant and compare it to peers, right in your chat.
